Navigation Links
Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs

THE WOODLANDS, Texas, Aug. 2 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.

"The encouraging results we have obtained with our portfolio of serotonin synthesis inhibitors, LX1031 for irritable bowel syndrome, LX1032 for carcinoid syndrome, and LX1033 for other gastrointestinal disorders, informed our decision to reacquire all development and commercialization rights to these promising drug candidates," said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer. "We have restructured our agreement with Symphony in a manner that enables us to both defer a sizable portion of the purchase option exercise price as well as make a significant portion contingent on the success of the drug candidates, allowing us to make payments as we receive licensing proceeds to fund them."

Lexicon and Symphony Icon Holdings agreed to revised terms under which Lexicon paid Symphony Icon Holdings $10 million upon closing and agreed to make certain additional deferred and contingent payments, payable at Lexicon's option in cash, common stock or a combination of cash and common stock, subject to certain conditions.  The additional deferred payments, which will be due on or before July 30, 2013, will be in an amount equal to $50 million less a 50% share of the expenses Lexicon incurs for the future development of LX1031, LX1032, LX1033 and related drug candidates, subject to certain exceptions and up to an aggregate reduction of $15 million.  Lexicon may make the deferred payments in whole or in part at any time that it chooses within the payment period.  The contingent payments will consist of a 50% share of any consideration Lexicon receives from licensing LX1031, LX1032, LX1033 and related drug candidates up to a maximum of $30 million plus the amount of any reduction in the deferred payment amount.  The contingent payments will be due if and when Lexicon receives such licensing consideration.  Lexicon will make an alternative contingent payment in lieu of a share of licensing consideration in the event that Lexicon receives regulatory approval in the United States for the marketing and sale of a product resulting from such programs prior to entering into a licensing transaction for the commercialization of such product in the United States.  The total of the up-front payment and all deferred and contingent payments by Lexicon will not exceed the $90 million exercise price applicable under the terms of the purchase option that were in effect before the restructured agreement was signed.

The deferred payments and the contingent payments may be paid in cash, common stock, or a combination of cash and common stock, at Lexicon's discretion, provided that at least 50% of any payment made on or prior to July 30, 2012 will be paid in common stock and no more than 50% of any payment made after such date will be paid in common stock.

LX1031 is an orally-delivered serotonin synthesis inhibitor that acts locally in the gastrointestinal tract targeting tryptophan hydroxylase (TPH), an enzyme necessary for the production of serotonin.  LX1031 recently demonstrated positive results in a Phase 2 clinical trial in patients with diarrhea-predominant and mixed forms of irritable bowel syndrome (IBS-D and IBS-M).  LX1032 is an orally-delivered serotonin synthesis inhibitor that acts peripherally to inhibit tryptophan hydroxylase without affecting brain serotonin levels.  LX1032 is currently in a Phase 2 clinical trial in patients with carcinoid syndrome.  LX1033 is a locally acting serotonin synthesis inhibitor with enhanced potency in IND-enabling studies.

Lexicon Conference Call:

Lexicon management will hold a conference call to discuss its reacquisition of the Symphony Icon programs at 3:00 p.m. Eastern Time on August 2, 2010.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 91995968.  An archived version of the conference call will be available on the Lexicon website through August 9, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032 and LX1033 and the potential therapeutic and commercial potential of LX1031, LX1032 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
4. Lexicon to Present at BIO International Convention
5. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
6. Lexicon Announces Proposed $95 Million Common Stock Offering
7. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
8. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
9. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
10. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
11. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... ... and teleradiology services, has added Chris Hafey and Claude Hooton to its board ... Radiological Society of North America (RSNA) 2015 Annual Meeting and continues to strategically ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch can ... "I conceived of this design due to personal experience with a bad back," he ... relaxation and convenience, as well as increases support. It also makes it easier to ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
Breaking Medicine News(10 mins):